{'fraction_non_alphanumeric': 0.028052805280528052, 'fraction_numerical': 0.009900990099009901, 'mean_word_length': 5.457446808510638, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Long‐term outcomes of robot‐assisted radical prostatectomy: Where do we stand?

Radical prostatectomy (RP) currently represents one of the most commonly performed therapeutic procedures for patients with clinically localised prostate cancer. After its introduction in the year 2000, robot-assisted RP (RARP) has rapidly spread over the USA and Europe, and today most RPs in these countries are performed robotically [1]. Of note, the rapid diffusion of minimally invasive surgery occurred even in the absence of level 1 data supporting the safety and effectiveness of RARP in patients with prostate cancer.